Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Shares of Cardinal Health Inc. CAH advanced 1.82% to $127.45 Wednesday, on what proved to be an all-around great trading ...

Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Dublin, Ohio-based Cardinal Health, Inc. (CAH) manufactures and distributes pharmaceuticals, medical & laboratory products, ...

Cardinal Health (NYSE:CAH – Get Free Report) had its price target upped by equities researchers at Wells Fargo & Company from ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

The global situation right now is a moving target, forcing many business owners to hope for the best and prepare for the ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

Cancer is a significant public health issue and economic burden, with breast cancer being the most prevalent among women in ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.